Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling

Simple item page
dc.contributor.authorDardis, Christopheren
dc.contributor.authorDonner, Daviden
dc.contributor.authorSanai, Naderen
dc.contributor.authorXiu, Joanneen
dc.contributor.authorMittal, Sandeepen
dc.contributor.authorMichelhaugh, Sharon K.en
dc.contributor.authorPandey, Manjarien
dc.contributor.authorKesari, Santoshen
dc.contributor.authorHeimberger, Amy B.en
dc.contributor.authorGatalica, Zoranen
dc.contributor.authorKorn, Michael W.en
dc.contributor.authorSumrall, Ashley L.en
dc.contributor.authorPhuphanich, Surasaken
dc.date.accessioned2021-06-28T15:04:35Zen
dc.date.available2021-06-28T15:04:35Zen
dc.date.issued2021-06-23en
dc.date.updated2021-06-27T03:14:37Zen
dc.description.abstractAbstract Background Gliosarcoma (GS) refers to the presence of mesenchymal differentiation (as seen using light microscopy) in the setting of glioblastoma (GB, an astrocytoma, WHO Grade 4). Although the same approach to treatment is typically adopted for GS and GB, there remains some debate as to whether GS should be considered a discrete pathological entity. Differences between these tumors have not been clearly established at the molecular level. Methods Patients with GS (n=48) or GB (n=1229) underwent molecular profiling (MP) with a pan-cancer panel of tests as part of their clinical care. The methods employed included next-generation sequencing (NGS) of DNA and RNA, copy number variation (CNV) of DNA and immunohistochemistry (IHC). The MP comprised 1153 tests in total, although results for each test were not available for every tumor profiled. We analyzed this data retrospectively in order to determine if our results were in keeping with what is known about the pathogenesis of GS by contrast with GB. We also sought novel associations between the MP and GS vs. GB which might improve our understanding of pathogenesis of GS. Results Potentially meaningful associations (p<0.1, Fisher’s exact test (FET)) were found for 14 of these tests in GS vs. GB. A novel finding was higher levels of proteins mediating immuno-evasion (PD-1, PD-L1) in GS. All of the differences we observed have been associated with epithelial-to-mesenchymal transition (EMT) in other tumor types. Many of the changes we saw in GS are novel in the setting of glial tumors, including copy number amplification in LYL1 and mutations in PTPN11. Conclusions GS shows certain characteristics of EMT, by contrast with GB. Treatments targeting immuno-evasion may be of greater therapeutic value in GS relative to GB.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationBMC Neurology. 2021 Jun 23;21(1):231en
dc.identifier.doihttps://doi.org/10.1186/s12883-021-02233-5en
dc.identifier.urihttp://hdl.handle.net/10919/104043en
dc.language.isoenen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.holderThe Author(s)en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleGliosarcoma vs. glioblastoma: a retrospective case series using molecular profilingen
dc.title.serialBMC Neurologyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.dcmitypeStillImageen

Files

Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
12883_2021_Article_2233.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download
Thumbnail Image
Name:
12883_2021_Article_2326.pdf
Size:
698.33 KB
Format:
Adobe Portable Document Format
Description:
Correction
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Journal Articles, BioMed Central and SpringerOpen
Destination Area: Adaptive Brain and Behavior (ABB)
Scholarly Works, Fralin Biomedical Research Institute at VTC